In the neoadjuvant setting postmenopausal patients with EGFR-positive, and ERα-positive breast cancer were randomized for gefitinib (EGFR tyrosine kinase inhibitor) alone or gefitinib plus anastrazole, an aromatase inhibitor. Here, CYP19A1 is linked to breast carcinoma.